Total
0
Shares
Immutep (ASX:IMM) - CEO, Marc Voigt
CEO, Marc Voigt
Source: Terrapinn Asia
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Immutep (IMM) has reported that its manufacturing partner has made significant progress in the cell line development for IMP761
  • This is the company’s preclinical candidate for treating the root cause of some autoimmune diseases by targeting the LAG-3 receptor on T cells
  • Immutep will now proceed with preparations for the Good Manufacturing Practice process which will then allow for clinical testing of the compound
  • Shares in Immutep are trading 3.03 per cent in the green for 17 cents

Immutep (IMM) has reported that its manufacturing partner has made significant progress in the cell line development for IMP761.

Manufacturer Batavia Biosciences used its STEP mAB technology to develop a stable, pharmaceutical-grade CHO cell line to produce high yields of IMP761.

This is Immutep’s preclinical candidate for treating the root cause of some autoimmune diseases by targeting the LAG-3 receptor of T cells.

“IMP761 is the first agonist antibody that targets the immune checkpoint LAG-3 for the treatment of autoimmune diseases, such as inflammatory bowel diseases, rheumatoid arthritis, and multiple sclerosis,” explained Immutep CEO Marc Voigt.

“The cell line which was developed seems to be highly potent and we are excited to be moving closer to clinical testing of this promising product candidate to treat the root cause of autoimmune diseases,” he continued.

IMP761 is an immunosuppressive agonist antibody to LAG-3 meaning that it binds to the LAG-3 receptor on activated T cells which form part of the body’s immune response.

By binding to the receptor, the agonist antibody inhibits the T cell’s proliferation and reaction against the body’s own tissue. In doing so, IMP761 is thought to reduce the excessive immune reaction associated with autoimmune diseases by addressing the cause rather than the subsequent inflammation.

Immutep will now proceed with preparations for the Good Manufacturing Practice process compliance phase, which will then allow for clinical testing of IMP761 in autoimmune diseases.

Company shares are trading 3.03 per cent in the green for 17 cents at 12:09 pm AEST.

IMM by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.